KYNTRA BIO, INC. Balance Sheet
KYNB|11 years of annual SEC 10-K data (FY2015-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 11 fiscal years. All figures from audited SEC 10-K filings.
KYNTRA BIO, INC. had $120M in total assets with negative shareholders' equity of $30M as of FY2025. Total debt was $75M against $48M in cash, resulting in $27M net debt.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.33 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.9M | $50.5M | $113.7M | $155.7M | $678.4M | $678.4M | $126.3M | $89.3M | $173.8M | $165.5M | $76.3M |
| Accounts Receivable | $216.0K | $481.0K | $12.6M | $16.3M | $41.9M | $41.9M | $28.5M | $63.7M | $8.5M | $10.4M | $15.4M |
| Inventory | $3.7M | $3.2M | $41.6M | $40.4M | $16.5M | $16.5M | $6.9M | - | - | - | - |
| Current Assets | $99.1M | $196.5M | $331.6M | $492.8M | $755.1M | $755.1M | $702.5M | $690.0M | $749.0M | $266.5M | $200.6M |
| PP&E (Net) | - | - | $13.1M | $20.6M | $33.6M | $33.6M | $42.7M | $127.2M | $129.5M | $123.7M | $129.0M |
| Total Assets | $119.6M | $214.5M | $423.5M | $610.1M | $826.8M | $826.8M | $857.4M | $880.6M | $898.6M | $469.6M | $470.6M |
| Current Liabilities | $29.2M | $133.3M | $217.7M | $273.6M | $163.2M | $163.2M | $102.7M | $89.0M | $77.3M | $65.1M | $67.2M |
| Total Debt | $75.0M | - | - | - | - | - | - | - | - | - | - |
| Shareholders' Equity | -$30.0M | -$225.6M | -$204.2M | -$21.4M | $422.2M | $422.2M | $516.1M | $509.2M | $563.2M | $155.8M | $177.6M |